Drug Profile
FOL 00X
Alternative Names: FOL-00XLatest Information Update: 14 Sep 2022
Price :
$50
*
At a glance
- Originator Follicum AB
- Developer Coegin Pharma
- Class Peptides; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Hirsutism
Most Recent Events
- 15 Sep 2021 Suspended - Preclinical for Hirsutism in Sweden
- 10 Apr 2018 Preclinical trials in Hirsutism in Sweden (unspecified route) (Follicum AB pipeline, April 2018)